Company intelligence / Profile preview

Sirtex

United States

Ownership: Private
Employees: ~201
Development stage: Other

Overview

Sirtex's SIR-Spheres Y-90 resin microspheres are FDA-approved and have global regulatory clearances for the treatment of unresectable liver cancers including hepatocellular carcinoma and colorectal cancer liver metastases, demonstrating ability to deliver targeted internal radiation that improves local tumor control and offers minimally invasive treatment.

Therapeutic areas: Oncology
Modalities: DeviceRadiopharmaceutical
Industry: Therapeutic Medical Devices

Partnerships

MIM Software Inc.

Beyond the preview

Go deeper on Sirtex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sirtex.

Explore the full profile